DuPont/Mallinckrodt patent suit
Executive Summary
Mallinckrodt will continue to market pyrophosphate radiopharmaceutical products following the settlement of a patent infringement suit with DuPont. Earlier, a U.S. district court ruled in favor of DuPont, which in 1984 filed an infringement action relating to three DuPont patents covering certain pyrophosphate radiopharmaceuticals. Under the settlement, announced Jan. 18, DuPont will be compensated for past infringement and will receive royalties from Mallinckrodt.